JP2005530771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530771A5 JP2005530771A5 JP2004503057A JP2004503057A JP2005530771A5 JP 2005530771 A5 JP2005530771 A5 JP 2005530771A5 JP 2004503057 A JP2004503057 A JP 2004503057A JP 2004503057 A JP2004503057 A JP 2004503057A JP 2005530771 A5 JP2005530771 A5 JP 2005530771A5
- Authority
- JP
- Japan
- Prior art keywords
- different
- same
- complex
- complex according
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000006495 integrins Human genes 0.000 description 7
- 108010044426 integrins Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 229940088623 biologically active substance Drugs 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- -1 C 6 hydrocarbon Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DXYNJHYPRKUMLM-WRBBJXAJSA-N 2,3-bis[(z)-octadec-9-enoxy]propyl-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]-dimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCOCCOCCO)OCCCCCCCC\C=C/CCCCCCCC DXYNJHYPRKUMLM-WRBBJXAJSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- HBZFNHMNLAOGPI-JDVCJPALSA-N CCCCCCCC/C=C\CCCCCCCC(OC(C)C(C)OC(CCCCCCC/C=C\CCCCCCCC)=O)=O.CN(C)C Chemical compound CCCCCCCC/C=C\CCCCCCCC(OC(C)C(C)OC(CCCCCCC/C=C\CCCCCCCC)=O)=O.CN(C)C HBZFNHMNLAOGPI-JDVCJPALSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0210538.5A GB0210538D0 (en) | 2002-05-08 | 2002-05-08 | Lipids and gene delivery |
| PCT/GB2003/001985 WO2003094974A1 (en) | 2002-05-08 | 2003-05-08 | Complexes for the delivery of biologically-active material to cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530771A JP2005530771A (ja) | 2005-10-13 |
| JP2005530771A5 true JP2005530771A5 (enExample) | 2006-06-22 |
Family
ID=9936285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004503057A Pending JP2005530771A (ja) | 2002-05-08 | 2003-05-08 | 生物学的活性物質の細胞への運搬に適した複合体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1506019A1 (enExample) |
| JP (1) | JP2005530771A (enExample) |
| AU (1) | AU2003240997A1 (enExample) |
| GB (1) | GB0210538D0 (enExample) |
| WO (1) | WO2003094974A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313132D0 (en) | 2003-06-06 | 2003-07-09 | Ich Productions Ltd | Peptide ligands |
| WO2005117985A2 (en) * | 2004-06-02 | 2005-12-15 | Ucl Biomedica Plc | Lipopolyplex construct with an integrin binding peptide for delivery of nucleic acids, peptides or drugs |
| DK2355851T3 (en) | 2008-11-10 | 2018-06-25 | Arbutus Biopharma Corp | Newly known lipids and compositions for release of therapeutic agents |
| EP4207205A4 (en) * | 2020-08-31 | 2025-02-26 | Takeda Pharmaceutical Company Limited | Inference device, inference method, inference program, model generating method, inference service providing system, inference service providing method, and inference service providing program |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| ES2299232T3 (es) * | 1995-09-11 | 2008-05-16 | La Jolla Cancer Research Foundation | Moleculas que migran hacia un organo o tejido seleccionado in vivo. |
| US5869715A (en) * | 1995-09-27 | 1999-02-09 | The Reagents Of The University Of California | Polyfunctional cationic cytofectins |
| AU7078396A (en) * | 1995-09-27 | 1997-04-30 | Regents Of The University Of California, The | Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes |
| GB9711115D0 (en) * | 1997-05-29 | 1997-07-23 | Inst Of Child Health | Integrin-targeting vectors having enhanced transfection activity |
| JP4800485B2 (ja) * | 1999-03-26 | 2011-10-26 | バイカル インコーポレイテッド | ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法 |
| CA2375727C (en) * | 1999-05-28 | 2010-05-25 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
-
2002
- 2002-05-08 GB GBGB0210538.5A patent/GB0210538D0/en not_active Ceased
-
2003
- 2003-05-08 AU AU2003240997A patent/AU2003240997A1/en not_active Abandoned
- 2003-05-08 WO PCT/GB2003/001985 patent/WO2003094974A1/en not_active Ceased
- 2003-05-08 JP JP2004503057A patent/JP2005530771A/ja active Pending
- 2003-05-08 EP EP03730315A patent/EP1506019A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230132645A1 (en) | Lipid membrane structure for delivery into sirna cell | |
| Habrant et al. | Design of ionizable lipids to overcome the limiting step of endosomal escape: application in the intracellular delivery of mRNA, DNA, and siRNA | |
| US4897355A (en) | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor | |
| WO2022140239A1 (en) | Nanomaterials comprising carbonates | |
| JP4714289B2 (ja) | リン脂質類似化合物 | |
| CN114073677B (zh) | 一种脂质纳米颗粒 | |
| EP4281064A1 (en) | Nanomaterials comprising an ionizable lipid | |
| JP2017500865A (ja) | レプチンｍＲＮＡの組成物および製剤 | |
| JP7821776B2 (ja) | 効率的な核酸送達のための担体 | |
| US20250381139A1 (en) | Multi-tail type ionizable lipid, preparation method therefor and use thereof | |
| JP6605477B2 (ja) | 核酸送達のためのカチオン性脂質 | |
| JP2010504929A (ja) | 生体系への送達を高める手段及び方法 | |
| WO2024014512A1 (ja) | 核酸内封脂質ナノ粒子の凍結乾燥組成物 | |
| JP2005530771A5 (enExample) | ||
| TWI876778B (zh) | 用於傳遞核酸的基於環烷的脂質化合物以及包括其之脂質奈米粒子 | |
| EA018111B1 (ru) | Конъюгаты белок-полимер и способ лечения инфекции вируса гепатита c или гепатита b | |
| CN113403313A (zh) | 一种特异识别人PLK1位点的sgRNA、质粒、纳米复合物和应用 | |
| CN118271388A (zh) | 一种类固醇-阳离子脂质化合物及其应用 | |
| JP6774965B2 (ja) | カチオン性脂質としての化合物 | |
| WO2024131717A1 (zh) | 一种阳离子脂质材料的制备及应用 | |
| WO2025224684A1 (en) | Compositions and methods for producing engineered immune cells | |
| WO2025161943A1 (zh) | 用于递送的脂质化合物和脂质纳米颗粒 | |
| CN121378329A (zh) | 一种磷硫化可电离脂质及其制备方法和应用 | |
| WO2025063214A1 (ja) | 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法 | |
| EA022354B1 (ru) | Терапевтическое применение конъюгатов интерферон-пэг |